Programmed cell death ligand 1 (PD‐L1) expression is not a predominant feature in Ewing sarcomas
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: Programmed cell death 1 (PD‐1) receptor engagement on T cells by its ligand programmed cell death ligand 1 (PD‐L1) is a key mechanism of immune escape, and antibody blockade of the interaction has emerged as an effective immunotherapeutic strategy in some cancers. The role and relevance of the PD‐1 checkpoint in Ewing sarcoma (EwS) is not yet understood. Procedure: Here, we investigated expression of PD‐L1 and PD‐1 in EwS by immunohistochemistry analysis of pretherapeutic tumor biopsies and in tumor xenografts following treatment with human T cells engineered to express a chimeric antigen receptor (CAR) against the tumor‐associated antigen G D2. PD‐L1 surface expression in EwS cell lines was assessed by flow cytometry. Results: PD‐L1 expression was not detectable on tumor cells in any of the 60 EwS biopsies. Infiltrating PD‐L1 positive T cells were found in one tumor, and four biopsies contained PD‐1‐positive T cells. Of 13 EwS cell lines, none constitutively expressed PD‐L1 on the cell surface. Interferon‐γ cytokine stimulation induced upregulation of the ligand on all cell lines. Adoptive therapy with CAR gene‐modified T cells in a mouse model did not induce PD‐L1 expression in EwS xenografts despite tumor infiltration with PD‐1+ CD3+ T cells. Conclusions: EwS cells can upregulate PD‐L1 under inflammatory conditions, but do not express the ligand in the pretherapeutic tumor microenvironment or postexposure to CAR T cells. PD‐1 checkpoint blockade alone is thus unlikely to evoke potent immune responses against EwS. Identification of the relevant immune evasion strategies in EwS will be vital for the development of effective immune targeting strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Cited by
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Self-citationSarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials
Zhu, M. M. T., Shenasa, E., & Nielsen, T. O. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102115 · Cited by 75
Metadata
- Authors
- Spurny, C., Kailayangiri, S., Jamitzky, S., Altvater, B., Wardelmann, E., Dirksen, U., Hardes, J., Hartmann, W., & Rossig, C.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2017-09-04
- Volume
- 65
- Issue
- 1
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2752504871
- Cited by
- 48
- References
- 14
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Programmed cell death ligand 1 (PD‐L1) expression is not a predominant feature in Ewing sarcomas. https://app.cochat.ai/papers/10.1002/pbc.26719
- The paper
- Spurny, C., Kailayangiri, S., Jamitzky, S., Altvater, B., Wardelmann, E., Dirksen, U., Hardes, J., Hartmann, W., & Rossig, C. (2018). Programmed cell death ligand 1 (PD‐L1) expression is not a predominant feature in Ewing sarcomas. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.26719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.